In a 1992 study in rats, the major finding was that intraperitoneal DSIP injection increased the concentration of substance P a neurotransmitter positively correlated with the regulation of anxiety and mood15 in the hypothalamus, suggesting to the researchers that the peptide sharply decreases the classical manifestations of stress.16 Earlier studies in humans, namely a series of five trials published in 1983, came to similar conclusions, with better relaxation and apparently improved tolerance against psychic stress reported by the subjects.17 Its possible that the improved stress and anxiety markers were consequent to DSIP-associated sleep enhancements.18 Substance use recovery A study from 1984 published in European Neurology describes DSIPs potential use as a treatment for alcohol and opiate use disorders
The strategy is additive: combine semaglutide with a long-acting amylin analog to improve weight and metabolic outcomes
However, it is not FDA-approved for medical treatment or injection, and regulatory status may vary by use
BPC-157 first appeared in the early 1990s, when European researchers wondered why some stomach ulcers healed quickly while others didnt, Flynn McGuire, a physical medicine and rehabilitation resident at the University of Utah who is about to enter a sports medicine fellowship, tells Outside Run
